Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSEzetimibe-d4 is intended for use as an internal standard for the quantification of ezetimibe (Item No. 16331) by GC- or LC-MS. Ezetimibe inhibits intestinal cholesterol absorption by preventing cholesterol uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter located in the apical membrane of enterocytes.1,2 Upon oral administration ezetimibe undergoes rapid glucuronidation in the intestine where its glucuronide binds NPC1L1.1,2 Ezetimibe exhibits ED50 values of 0.0005-0.05 mg/kg in various animal models, selectively blocking cholesterol absorption without inhibiting pancreatic lipolytic enzyme activities in the intestinal lumen, affecting bile acid micelle solubilization of cholesterol, or interfering with the absorption of triglycerides, fatty acids, or bile acids.1,3
WARNING This product is not for human or veterinary use.
1. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol. 69, 221-248 (2007).
2. The target of ezetimibe is Niemann-
3. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 62(16), 2333-2347 (2002).